Comparer des méthodes

	Échelle d'évaluation fonctionnelle révisée pour la SLA (ALSFRS-R)	Échelle de marche pour la sclérose en plaques-12 (MSWS-12)
Domaine	Neurologie	Neurologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	1999	2003
Auteur d'origine	James M. Cedarbaum, NIH/NINDS	Jeremy C. Hobart, University of Plymouth
Type	Clinician-rated and patient-reported hybrid	Self-report questionnaire
Source fondatrice	Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21.	Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36.
Alias	ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised	MS Walking Scale-12, MSWS
Apparentées	4	3
Résumé	The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions.	The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility.